Sunitinib-induced reversible posterior leukoencephalopathy syndrome after rifampin discontinuation / 대한내과학회지
Korean Journal of Medicine
; : S188-S191, 2009.
Article
em Ko
| WPRIM
| ID: wpr-139798
Biblioteca responsável:
WPRO
ABSTRACT
Sunitinib is an oral tyrosine kinase inhibitor with anti-angiogenic activity that is used for the treatment of advanced renal cell carcinoma and advanced gastrointestinal stromal tumors after failure on imatinib. The most common adverse effects of sunitinib are fatigue, diarrhea, nausea, stomatitis, hypertension, hand-foot syndrome, and cytopenia. Sunitinib was recently reported to be associatedwith reversible posterior leukoencephalopathy syndrome (RPLS). Here, we report the case of a 76-year-old woman with sunitinib- induced RPLS that developed after rifampin discontinuation.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Piperazinas
/
Pirimidinas
/
Pirróis
/
Rifampina
/
Estomatite
/
Benzamidas
/
Proteínas Tirosina Quinases
/
Carcinoma de Células Renais
/
Tumores do Estroma Gastrointestinal
/
Diarreia
Limite:
Aged
/
Female
/
Humans
Idioma:
Ko
Revista:
Korean Journal of Medicine
Ano de publicação:
2009
Tipo de documento:
Article